Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer

References

• Arnold M, Karim-Kos HE, Coebergh JW, et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 2015;51(9):1164–1187.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration- resistant prostate cancer. EurUrol. 2014;65:467–479.
   Google Scholar
• Bambury RM, Rathkopf DE. Novel and next-generation androgen receptor-directed therapies for prostate cancer: beyond abiraterone and enzalutamide. Urol Oncol. 2015 Jul 7. [Epub ahead of print]. pii: S1078-1439(15)00269-0. doi:10.1016/j.urolonc.2015.05.025.
   Google Scholar
• Attard G, Reid AH, A’Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27(23):3742–3748.
   PubMed Web of Science ®Google Scholar
• Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–1446.
   PubMed Web of Science ®Google Scholar
• Hughes IA, Davies JD, Bunch TI, et al. Androgen insensitivity syndrome. Lancet. 2012;380:1419–1428.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 1997;94:3320–3323.
   PubMed Web of Science ®Google Scholar
• Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001–3015.
   PubMed Web of Science ®Google Scholar
• Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011;57:1366–1375.
   PubMed Web of Science ®Google Scholar
• DeMaeseneer DJ, VanPraet C, Lumen N, et al. Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. Urol Oncol: Semin Invest. 2015;33:310–321.
   PubMed Web of Science ®Google Scholar
• Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 1997;57:4511–4516.
   PubMed Web of Science ®Google Scholar
• Cunha GR, Cooke PS, Kurita T. Role of stromal epithelial interactions in hormonal responses. Arch Histol Cytol. 2004;67:417–434.
   PubMedGoogle Scholar
• Schrecengost R, Knudsen KE. Molecular pathogenesis and progression of prostate cancer. Semin Oncol. 2013;40:244–258.
   PubMed Web of Science ®Google Scholar
• Pinto A. Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther. 2014;15(2):149–155.
   PubMed Web of Science ®Google Scholar
• Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 2000;42:150–160.
   PubMed Web of Science ®Google Scholar
• Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010;24:1967–2000.
   PubMed Web of Science ®Google Scholar
• Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–278.
   PubMed Web of Science ®Google Scholar
• Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009;69:8141–8149.
   PubMed Web of Science ®Google Scholar
• Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids. 2015;95:80–87.
   PubMed Web of Science ®Google Scholar
• Kimura K, Markowski M, Bowen C, et al. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 2001;61:5611–5618.
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447–4454.
   PubMed Web of Science ®Google Scholar
• Kudahetti S, Fisher G, Ambroisine L, et al. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int. 2009;104:20–24.
   PubMed Web of Science ®Google Scholar
• Russo G, Mischi M, Scheepens W, et al. Angiogenesis in prostate cancer: onset, progression and imaging. BJU Int. 2012;110:E794–808.
   PubMed Web of Science ®Google Scholar
• Steinkamp MP, O’Mahony OA, Brogley M, et al. Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res. 2009;69:4434–4442.
   PubMed Web of Science ®Google Scholar
• Dehm SM, Schmidt LJ, Heemers HV, et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469–5477.
   PubMed Web of Science ®Google Scholar
• Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009;69:2305–2313.
   PubMed Web of Science ®Google Scholar
• Gao H, Ouyang X, Banach-Petrosky WA, et al. Emergence of androgen independence at early stages of prostate cancer progression in nkx3.1; pten mice. Cancer Res. 2006;66:7929–7933.
   PubMed Web of Science ®Google Scholar
• Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKa controls prostate cancer metastasis by repressing Maspin. Nature. 2007;446:690–694.
   PubMed Web of Science ®Google Scholar
• Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012;110(Suppl 1):23–29.
   PubMedGoogle Scholar
• Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem. 2011;19:6383–6399.
   PubMed Web of Science ®Google Scholar
• Zhu H, Garcia JA. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor. Curr Oncol Rep. 2013;15:105–112.
   PubMed Web of Science ®Google Scholar
• Yamaoka M, Hara T, Hitaka T, et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012;129:115–128.
   PubMed Web of Science ®Google Scholar
• Dreicer R, MacLean D, Suri A, et al. Phase I/II trial of orteronel (TAK-700) - an investigational 17,20-lyase inhibitor - in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014;20(5):1335–1344.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Ozono S, Yamaguchi A, et al. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2015;75:373–380.
   PubMed Web of Science ®Google Scholar
• Hussain M, Corn PG, Michaelson MD, et al. Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration- resistant prostate cancer and rising prostate-specific antigen. Clin Cancer Res. 2014;20(16):4218–4227.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Gandhi JG, Clark WR, et al. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel–prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015;33:397–408.
   PubMed Web of Science ®Google Scholar
• Njar VCO, Brodie AMH. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J Med Chem. 2015;58:2077–2087.
   PubMed Web of Science ®Google Scholar
• Brodie AM, Dowsett M, Coombes RC. Aromatase inhibitors as new endocrine therapy for breast cancer. Cancer Treat Res. 1988;39:51−65.
   PubMedGoogle Scholar
• Handratta VD, Vasaitis TS, Njar VC, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/ antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem. 2005;48:2972–2978.
   PubMed Web of Science ®Google Scholar
• Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of 17α-hydroxylase/17,20-lyase inhibitor 3β-hydroxy-17-(1H-benzimidazole-1-yl) androsta-5,16-diene in prostate cancer. Mol Cancer Ther. 2008;7:2348–2357.
   PubMed Web of Science ®Google Scholar
• Yu Z, Cai C, Gao S, et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res. 2014;20(15):4075–4085.
   PubMed Web of Science ®Google Scholar
• Purushottamachar P, Godbole AM, Gediya LK, et al. Systematic structure modifications of multi-target prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem. 2013;56(12):4880−98.
   PubMed Web of Science ®Google Scholar
• Nakouzi NA, Wang C, Bishop JL, et al. In galeterone suppresses castration-resistant and enzalutamide-resistant prostate cancer growth in vitro. AACR-NCI-EORTC 2013 International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, Oct 19−23; American Association for Cancer Research: Philadelphia, PA, 2013; p C89.
   Google Scholar
• Montgomery G, Eisenberger M, Rettig M, et al. In phase 1 clinical trial of galeterone (TOK-001) a multifunctional antiandrogen and CYP17 inhibitor in Castration Resistant Prostate Cancer (CRPC); 2012 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, Jun 1−5; American Society of Clinical Oncology: Alexandria, VA, 2012; p 4665.
   Google Scholar
• Taplin M-E, Chu F, Morrison JP. Et al. In ARMOR1: safety of galeterone (TOK-001) in a phase 1 clinical trial in chemotherapy naive patients with castration-resistant prostate cancer (CRCP). 2012 American Association for Cancer Research Meeting, Chicago, IL, Mar 31−Apr 4; American Association for Cancer Research: Philadelphia, PA, 2012; pp CT–07.
   Google Scholar
• Kramer WG, Vince B, McGarry C. In comparison of the Pharmacokinetics (PK) of galeterone novel oral formulations. 2013 Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, May 31−Jun 4; American Society of Clinical Oncology: Alexandria, VA, 2013; p e16075.
   Google Scholar
• Montgomery G, Eisenberger MA, Heath EI, et al. Galeterone in men with CRPC: results in four distinct patient populations from ARMOR2 study. 2014 Meeting of the American Society of Clinical Oncology (ASCO), May 3−Jun 3, 2014; American Society of Clinical Oncology (ASCO): Alexandria, VA, 2014.
   Google Scholar
• Taplin M-E, Montgomery RB ARMOR2: galeterone in progressive CRPC patients who have failed primary therapy. 2014 American Society of Clinical Genitourinary Cancers Symposium (ASCO GU), San Francisco, CA, Jan 30−Feb 2, 2014; American Society of Clinical Oncology (ASCO): Alexandria, VA, 2014; p 71.
   Google Scholar
• Rafferty SW, Eisner JR, Moore WR, et al. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorg Med Chem Lett. 2014;24:2444–2447.
   PubMed Web of Science ®Google Scholar
• Yin L, Hu Q, Hartmann RW. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci. 2013;14:13958–13978.
   PubMed Web of Science ®Google Scholar
• Eisner JR, Abbott DH, Bird IM, et al. Assessment of steroid hormones upstream of P450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA). Endocr Rev. 2012;33( 03_MeetingAbstracts):SAT–266.
   Google Scholar
• Abbott DH, Eisner JR, Bird IM, et al. Plasma steroid concentrations in male rhesus monkeys following treatment with the P450c17 (CYP17) inhibitors VT-464 and abiraterone acetate: A comparison to human 17,20-Lyase (lyase) and combined lyase/17α-hydroxylase (hydroxylase) deficiencies. Endocr Rev. 2012;33( 03_MeetingAbstracts):SAT–256.
   Google Scholar
• Toren PJ, Kim S, Pham S, et al. Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther. 2015;14(1):59–69.
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494–1503.
   PubMed Web of Science ®Google Scholar
• Patel JC, Maughan BL, Agarwal AM, et al. Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer. 2013;2013:981684.
   PubMedGoogle Scholar
• Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19:575–586.
   PubMed Web of Science ®Google Scholar
• Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013;3:1020–1029.
   PubMed Web of Science ®Google Scholar
• Jentzmik F, Azoitei A, Zengerling F, et al. Androgen receptor aberrations in the era of abiraterone and enzalutamide. World J Urol. 2015 Jun 23. doi:10.1007/s00345-015-1624-2. [Epub Ahead of Print].
   Web of Science ®Google Scholar
• Nelson WG, Yegnasubramanian S. Resistance emerges to second-generation antiandrogens in prostate cancer. Cancer Discov. 2013;3(9):971–974.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525–3530.
   PubMed Web of Science ®Google Scholar
• Rathkopf DE, Antonarakis ES, Shore ND, et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2013;31(suppl 6). Abstract 48.
   PubMed Web of Science ®Google Scholar
• Smith MR, Antonarakis ES, Ryan CJ, et al. ARN-509 in men with high-risk nonmetastatic castration-resistant prostate cancer (mCRPC) [abstract]. J Clin Oncol. 2013;31(suppl6). Abstract 07.
   Google Scholar
• Kim W, Ryan CJ. Quo Vadis: advanced prostate cancer—Clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015;121:361–371.
   PubMed Web of Science ®Google Scholar
• Aggarwal RR, Alumkal JJ, Szmulewitz RZ, et al. The role of highly selective androgen receptor (AR) targeted therapy in men with biochemically relapsed hormone sensitive prostate cancer. J Clin Oncol. 2015;33(suppl; abstr TPS5084).
   PubMed Web of Science ®Google Scholar
• Karantanos T, Evans CP, Tombal B, et al. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015;67:470–479.
   PubMed Web of Science ®Google Scholar
• Leibowitz-Amit R, Joshua AM. Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol. 2012;19(suppl 3):S22–31.
   PubMed Web of Science ®Google Scholar
• Moilanen A-M, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015 Jul 3;5:12007.
   PubMed Web of Science ®Google Scholar
• Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013;2:e00499.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open- label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975–985.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Castaneda S, Dumble M, et al. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther. 2011;10(12):2309–2319.
   PubMed Web of Science ®Google Scholar
• Bianchini D, Omlin A, Pezaro C, et al. First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Bjc. 2013;109:2579–2586.
   PubMed Web of Science ®Google Scholar
• Loddick SA, Ross SJ, Thomason AG, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther. 2013;12:1715–1727.
   PubMed Web of Science ®Google Scholar
• Bradbury RH, Acton DG, Broadbent NL, et al. Discovery of AZD3514, a small molecule androgen receptor downregulator for treatment of advanced prostate cancer. Bioorg Med Chem Lett. 2013;23(7):1945–1948.
   PubMed Web of Science ®Google Scholar
• Cummings J, Sloane R, Morris K, et al. Optimisation of an immune-histochemistry method for the determination of androgen receptor expression levels in circulating tumour cells. BMC Cancer. 2014;14:226–233.
   PubMed Web of Science ®Google Scholar
• Omlin A, Jones RJ, van der Noll R, et al. AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. Invest New Drugs. 2015;33:679–690.
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol. 2012;44:1646–1656.
   PubMed Web of Science ®Google Scholar
• Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone refractory prostate cancer. Cancer Research. 2004;64:6595–6602.
   PubMed Web of Science ®Google Scholar
• Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Research. 2005;65:11083–11093.
   PubMed Web of Science ®Google Scholar
• Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research. 2007;67:10455–10465.
   PubMed Web of Science ®Google Scholar
• Andrieu C, Taieb D, Baylot V, et al. Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E. Oncogene. 2010;29:1883–1896.
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Yu EY, Hirte HW, et al. Phase I trial of OGX-427, a 2ʹmethoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): final results. J Clin Oncol. 2010;28:15s. suppl abstr 3077
   Google Scholar
• Shiota M, Bishop JL, Nip KM, et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 2013;73(10):3109–3119.
   PubMed Web of Science ®Google Scholar
• Chi KN, Hotte SJ, Ellard S, et al. A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. J Clin Oncol. 2012;30. suppl 5:abstract 121.
   Web of Science ®Google Scholar
• D’Antonio JM, Van der Griend DJ, Isaacs JT. DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer. 2009;16:325–332.
   PubMed Web of Science ®Google Scholar
• Denmeade SR, Isaacs JT. Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate. 2010;70:1600–1607.
   PubMed Web of Science ®Google Scholar
• Isaacs JT, D’Antonio JM, Chen S, et al. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate. 2012;72:1491–1505.
   PubMed Web of Science ®Google Scholar
• Morris MJ, Huang D, Kelly WK, et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol. 2009;56:237–244.
   PubMed Web of Science ®Google Scholar
• Schweizer MT, Antonarakis ES, Wang H, et al. Effect of bipolar androgen therapy for a symptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med. 2015;7:269ra2.
   PubMed Web of Science ®Google Scholar
• Wilken N, Scovell JM, Ramasamy R. Re: effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Eur Urol. 2015;68(3):538–539.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Gray PJ. From bench to bedside: bipolar androgen therapy in a pilot clinical study. Asian J Androl. 2015;17:767–768.
   PubMed Web of Science ®Google Scholar
• Teply BA, Antonarakis ES, Carducci MA, et al. A randomized phase II study comparing bipolar androgen therapy vs. enzalutamide in asymptomatic men with castration resistant metastatic prostate cancer: the TRANSFORMER trial. J Clin Oncol. 2015;33(suppl):abstr TPS5079.
   Google Scholar
• Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038.
   PubMed Web of Science ®Google Scholar
• Danila DC, Anand A, Sung CC, et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol. 2011;60:897–904.
   PubMed Web of Science ®Google Scholar